Published online
doi:10.1084/jem.20082113
The Journal of Experimental Medicine, Vol. 206, No. 3, 507-514
The Rockefeller University Press, 0022-1007 $30.00
© Louvet et al.
A novel myelin P0–specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy
Cédric Louvet,
Beniwende G. Kabre,
Dan W. Davini,
Nicolas Martinier,
Maureen A. Su,
Jason J. DeVoss,
Wendy L. Rosenthal,
Mark S. Anderson,
Hélène Bour-Jordan, and
Jeffrey A. Bluestone
Diabetes Center and the Department of Medicine, University of California, San Francisco, San Francisco, CA 94143
CORRESPONDENCE Jeffrey A. Bluestone: jbluest{at}diabetes.ucsf.edu
Autoimmune-prone nonobese diabetic mice deficient for B7-2 spontaneously develop an autoimmune peripheral neuropathy mediated by inflammatory CD4+ T cells that is reminiscent of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. To determine the etiology of this disease, CD4+ T cell hybridomas were generated from inflamed tissue–derived CD4+ T cells. A majority of T cell hybridomas were specific for myelin protein 0 (P0), which was the principal target of autoantibody responses targeting nerve proteins. To determine whether P0-specific T cell responses were sufficient to mediate disease, we generated a novel myelin P0–specific T cell receptor transgenic (POT) mouse. POT T cells were not tolerized or deleted during thymic development and proliferated in response to P0 in vitro. Importantly, when bred onto a recombination activating gene knockout background, POT mice developed a fulminant form of peripheral neuropathy that affected all mice by weaning age and led to their premature death by 3–5 wk of age. This abrupt disease was associated with the production of interferon
by P0-specific T cells and a lack of CD4+ Foxp3+ regulatory T cells. Collectively, our data suggest that myelin P0 is a major autoantigen in autoimmune peripheral neuropathy.
H. Bour-Jordan and J.A. Bluestone contributed equally to this paper.
© 2009 Louvet et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?